Published in J Virol on October 01, 2000
Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev (2003) 2.90
DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2001) 2.41
The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells. J Virol (2002) 2.32
Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes. J Virol (2002) 2.28
Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes. J Virol (2001) 2.25
Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? Annu Rev Microbiol (2003) 2.07
ORC, MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. J Virol (2004) 1.97
EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog (2006) 1.71
Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe (2010) 1.70
The gammaherpesvirus 68 latency-associated nuclear antigen homolog is critical for the establishment of splenic latency. J Virol (2003) 1.70
Disruption of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J Virol (2004) 1.64
The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3beta. J Virol (2003) 1.62
Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi's sarcoma-associated herpesvirus lytic transcription. J Virol (2006) 1.57
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood (2008) 1.52
Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res (2007) 1.47
Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA. Proc Natl Acad Sci U S A (2006) 1.43
Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program. Virology (2008) 1.41
Structure and function of latency-associated nuclear antigen. Curr Top Microbiol Immunol (2007) 1.39
Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol (2006) 1.36
The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J Virol (2007) 1.36
Epigenetic reprogramming of host genes in viral and microbial pathogenesis. Trends Microbiol (2010) 1.32
Analysis of chromatin attachment and partitioning functions of bovine papillomavirus type 1 E2 protein. J Virol (2004) 1.29
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. J Virol (2003) 1.28
The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr virus latent promoters. J Virol (2001) 1.24
Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif. J Virol (2004) 1.21
Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA. Virology (2007) 1.14
The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency. Future Microbiol (2011) 1.13
Chromatin organization of gammaherpesvirus latent genomes. Biochim Biophys Acta (2009) 1.12
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induces expression of the helix-loop-helix protein Id-1 in human endothelial cells. J Virol (2003) 1.11
Determination of Kaposi's sarcoma-associated herpesvirus C-terminal latency-associated nuclear antigen residues mediating chromosome association and DNA binding. J Virol (2007) 1.09
ORF73 of herpesvirus Saimiri strain C488 tethers the viral genome to metaphase chromosomes and binds to cis-acting DNA sequences in the terminal repeats. J Virol (2003) 1.07
Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas. J Virol (2010) 1.07
Identification of host-chromosome binding sites and candidate gene targets for Kaposi's sarcoma-associated herpesvirus LANA. J Virol (2012) 1.05
Poly(ADP-ribose) polymerase 1 binds to Kaposi's sarcoma-associated herpesvirus (KSHV) terminal repeat sequence and modulates KSHV replication in latency. J Virol (2004) 1.05
The Herpesvirus Saimiri open reading frame 73 gene product interacts with the cellular protein p32. J Virol (2002) 1.05
Proteomic analysis of the Kaposi's sarcoma-associated herpesvirus terminal repeat element binding proteins. J Virol (2006) 1.04
The interaction of the gammaherpesvirus 68 orf73 protein with cellular BET proteins affects the activation of cell cycle promoters. J Virol (2009) 1.01
Identification of a novel cellular transcriptional repressor interacting with the latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2003) 1.01
Regulation of the interaction between glycogen synthase kinase 3 and the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen. J Virol (2005) 1.01
The latency-associated nuclear antigen of rhesus monkey rhadinovirus inhibits viral replication through repression of Orf50/Rta transcriptional activation. J Virol (2005) 1.01
Role of Kaposi's sarcoma-associated herpesvirus C-terminal LANA chromosome binding in episome persistence. J Virol (2009) 0.99
DNA-binding and -bending activities of SAP30L and SAP30 are mediated by a zinc-dependent module and monophosphoinositides. Mol Cell Biol (2008) 0.99
Kaposi's sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation. J Virol (2008) 0.98
A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening. J Virol (2012) 0.98
Tissue specificity of the Kaposi's sarcoma-associated herpesvirus latent nuclear antigen (LANA/orf73) promoter in transgenic mice. J Virol (2002) 0.98
Activation of Kaposi's sarcoma-associated herpesvirus (KSHV) by inhibitors of class III histone deacetylases: identification of sirtuin 1 as a regulator of the KSHV life cycle. J Virol (2014) 0.97
The latency-associated nuclear antigen interacts with MeCP2 and nucleosomes through separate domains. J Virol (2009) 0.97
The latency-associated nuclear antigen homolog of herpesvirus saimiri inhibits lytic virus replication. J Virol (2003) 0.97
A structural basis for BRD2/4-mediated host chromatin interaction and oligomer assembly of Kaposi sarcoma-associated herpesvirus and murine gammaherpesvirus LANA proteins. PLoS Pathog (2013) 0.96
The single RBP-Jkappa site within the LANA promoter is crucial for establishing Kaposi's sarcoma-associated herpesvirus latency during primary infection. J Virol (2011) 0.95
Bub1 and CENP-F can contribute to Kaposi's sarcoma-associated herpesvirus genome persistence by targeting LANA to kinetochores. J Virol (2010) 0.94
The internal Kaposi's sarcoma-associated herpesvirus LANA regions exert a critical role on episome persistence. J Virol (2011) 0.94
LANA binds to multiple active viral and cellular promoters and associates with the H3K4methyltransferase hSET1 complex. PLoS Pathog (2014) 0.94
Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) beta expression by competing with IFN regulatory factor-3 for binding to IFNB promoter. J Biol Chem (2010) 0.93
The ubiquitin-specific protease USP7 modulates the replication of Kaposi's sarcoma-associated herpesvirus latent episomal DNA. J Virol (2012) 0.92
EBV is necessary for proliferation of dually infected primary effusion lymphoma cells. Cancer Res (2008) 0.92
Kaposi's sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylation. PLoS Pathog (2012) 0.91
The chromatin landscape of Kaposi's sarcoma-associated herpesvirus. Viruses (2013) 0.91
KSHV LANA--the master regulator of KSHV latency. Viruses (2014) 0.91
Role of chromatin during herpesvirus infections. Biochim Biophys Acta (2009) 0.91
HHV-8 encoded LANA-1 alters the higher organization of the cell nucleus. Mol Cancer (2007) 0.91
Disruption of LANA in rhesus rhadinovirus generates a highly lytic recombinant virus. J Virol (2009) 0.90
Kaposi's sarcoma-associated herpesvirus LANA protein downregulates nuclear glycogen synthase kinase 3 activity and consequently blocks differentiation. J Virol (2007) 0.90
Unbiased mutagenesis of MHV68 LANA reveals a DNA-binding domain required for LANA function in vitro and in vivo. PLoS Pathog (2012) 0.89
The viral etiology of AIDS-associated malignancies. Adv Pharmacol (2008) 0.89
Kaposi's sarcoma-associated herpesvirus-encoded LANA interacts with host KAP1 to facilitate establishment of viral latency. J Virol (2014) 0.89
Phosphorylation of the chromatin binding domain of KSHV LANA. PLoS Pathog (2012) 0.88
Ribosomal protein S6 interacts with the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2011) 0.88
Histone deacetylases in herpesvirus replication and virus-stimulated host defense. Viruses (2013) 0.87
Histone deacetylase classes I and II regulate Kaposi's sarcoma-associated herpesvirus reactivation. J Virol (2013) 0.87
Involvement of SSRP1 in latent replication of Kaposi's sarcoma-associated herpesvirus. J Virol (2009) 0.87
Molecular biology of KSHV lytic reactivation. Viruses (2015) 0.86
Development of a fluorescence-based assay to screen antiviral drugs against Kaposi's sarcoma associated herpesvirus. Mol Cancer Ther (2007) 0.86
Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication. Recent Results Cancer Res (2014) 0.84
Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma. PLoS One (2008) 0.83
Kaposi's sarcoma-associated herpesvirus-encoded LANA can induce chromosomal instability through targeted degradation of the mitotic checkpoint kinase Bub1. J Virol (2014) 0.81
Human Herpesvirus 8: Biology and Role in the Pathogenesis of Kaposi's Sarcoma and Other AIDS-related Malignancies. Curr Infect Dis Rep (2003) 0.81
Induction of hyaluronan production by oncogenic KSHV and the contribution to viral pathogenesis in AIDS patients. Cancer Lett (2015) 0.81
Activation of DNA Damage Response Induced by the Kaposi's Sarcoma-Associated Herpes Virus. Int J Mol Sci (2016) 0.80
Comprehensive analysis of LANA interacting proteins essential for viral genome tethering and persistence. PLoS One (2013) 0.80
Regulation of growth signalling and cell cycle by Kaposi's sarcoma-associated herpesvirus genes. Int J Exp Pathol (2004) 0.79
Glutamate secretion and metabotropic glutamate receptor 1 expression during Kaposi's sarcoma-associated herpesvirus infection promotes cell proliferation. PLoS Pathog (2014) 0.79
LANA-Mediated Recruitment of Host Polycomb Repressive Complexes onto the KSHV Genome during De Novo Infection. PLoS Pathog (2016) 0.78
Kaposi sarcoma herpes virus latency associated nuclear antigen protein release the G2/M cell cycle blocks by modulating ATM/ATR mediated checkpoint pathway. PLoS One (2014) 0.78
Kaposi's sarcoma-associated herpesvirus-encoded LANA down-regulates IL-22R1 expression through a cis-acting element within the promoter region. PLoS One (2011) 0.77
KSHV LANA and EBV LMP1 induce the expression of UCH-L1 following viral transformation. Virology (2013) 0.77
Co-infections and Pathogenesis of KSHV-Associated Malignancies. Front Microbiol (2016) 0.76
The Modulation of Apoptotic Pathways by Gammaherpesviruses. Front Microbiol (2016) 0.76
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med (1995) 21.16
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood (1995) 16.81
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A (1996) 12.89
Methylation-induced repression--belts, braces, and chromatin. Cell (1999) 9.89
Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell (1997) 8.99
Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med (1995) 8.52
Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell (1997) 7.64
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med (1995) 6.71
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science (1996) 6.57
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med (1996) 5.56
Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science (1999) 5.55
Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol (1996) 5.05
A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev (1998) 4.78
p53 inhibition by the LANA protein of KSHV protects against cell death. Nature (2000) 4.74
Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol (1998) 4.62
Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science (1998) 4.55
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol (1997) 4.45
A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature (1995) 4.40
Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol (1996) 4.26
A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J Virol (1998) 4.23
HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood (2000) 4.22
Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood (1996) 4.22
Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med (1996) 4.13
Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature (1996) 3.88
SAP30, a novel protein conserved between human and yeast, is a component of a histone deacetylase complex. Mol Cell (1998) 3.76
Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. J Clin Invest (1997) 3.71
Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61
Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science (1996) 3.31
Sin meets NuRD and other tails of repression. Cell (1999) 3.31
The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology (1999) 3.30
CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci U S A (1999) 2.81
The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol (1996) 2.65
Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol (2000) 2.55
Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter. J Virol (1999) 2.41
Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene. J Virol (1999) 2.36
Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. Virology (1999) 2.23
Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Natl Acad Sci U S A (2000) 2.15
Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome. J Hum Virol (1999) 2.09
Epstein-Barr virus shuttle vector for stable episomal replication of cDNA expression libraries in human cells. Mol Cell Biol (1988) 2.06
Novel organizational features, captured cellular genes, and strain variability within the genome of KSHV/HHV8. J Natl Cancer Inst Monogr (1998) 2.01
Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood (1998) 1.95
Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J Virol (1999) 1.70
Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood (1998) 1.55
Retracted Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. Proc Natl Acad Sci U S A (1999) 1.52
Contribution of conserved amino acids in mediating the interaction between EBNA2 and CBF1/RBPJk. J Virol (1995) 1.51
Posttransplantation plasmacytic proliferations related to Kaposi's sarcoma-associated herpesvirus. Am J Surg Pathol (1999) 1.49
Human herpesvirus-8-encoded LNA-1 accumulates in heterochromatin- associated nuclear bodies. J Gen Virol (1999) 1.49
Immunoglobulin VH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation. Am J Pathol (1998) 1.46
Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol (1995) 1.43
Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood (1997) 1.34
Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8. J Virol (1999) 1.32
Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am J Pathol (1999) 1.31
Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformation-associated antigens in an EBV- and human herpesvirus type 8-carrying body cavity lymphoma line. J Gen Virol (1998) 1.28
Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol Cell Biol (1997) 1.28
Differential methylation of Epstein-Barr virus latency promoters facilitates viral persistence in healthy seropositive individuals. J Virol (1999) 1.28
The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity. Proc Natl Acad Sci U S A (1999) 1.27
Persistent infection of Epstein-Barr virus-positive B lymphocytes by human herpesvirus 8. J Virol (1998) 1.19
Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood (1997) 1.18
p300 stimulates transcription instigated by ligand-bound thyroid hormone receptor at a step subsequent to chromatin disruption. EMBO J (1999) 1.16
Establishing and characterizing a CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma. J Med Virol (1999) 1.04
Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas. J Gen Virol (1994) 1.00
Human herpes virus 8 (Kaposi's sarcoma herpes virus) and malignant lymphoproliferations in France: a molecular study of 250 cases including two AIDS-associated body cavity based lymphomas. Leukemia (1997) 0.93
Primary body cavity-based AIDS-related lymphomas. Evolution of a new disease entity. Am J Clin Pathol (1996) 0.86
Characterization of intertypic recombinants of the Epstein-Barr virus from the body-cavity-based lymphomas cell lines BC-1 and BC-2. Virology (1999) 0.84
IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science (1997) 11.89
Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell (1985) 7.17
A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol (1988) 5.28
Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science (1994) 4.87
Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol (1996) 4.26
Promiscuous trans activation of gene expression by an Epstein-Barr virus-encoded early nuclear protein. J Virol (1986) 3.82
Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A (1980) 3.77
Differentiation of Mycobacterium tuberculosis isolates by spoligotyping and IS6110 restriction fragment length polymorphism. J Clin Microbiol (1997) 3.46
The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc Natl Acad Sci U S A (1993) 3.22
trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. J Virol (1992) 3.22
DNA of Epstein-Barr virus. I. Comparative studies of the DNA of Epstein-Barr virus from HR-1 and B95-8 cells: size, structure, and relatedness. J Virol (1975) 3.13
Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2. Science (1995) 2.96
Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med (1993) 2.96
Immunochemical characterization of a protein associated with Mycobacterium leprae cell wall. Infect Immun (1985) 2.88
CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci U S A (1999) 2.81
Specificity of antibodies to immunodominant mycobacterial antigens in pulmonary tuberculosis. J Clin Microbiol (1988) 2.79
Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today (1991) 2.71
A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (1996) 2.70
IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol Cell Biol (1999) 2.68
Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun (1999) 2.65
Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays. J Virol (1995) 2.63
Functional domains of Epstein-Barr virus nuclear antigen EBNA-1. J Virol (1991) 2.63
Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet (1991) 2.60
Transformation of mycobacterial species using hygromycin resistance as selectable marker. Microbiology (1994) 2.55
T lymphocytes respond to solid-phase antigen: a novel approach to the molecular analysis of cellular immunity. Immunology (1986) 2.45
Responsiveness of the Epstein-Barr virus NotI repeat promoter to the Z transactivator is mediated in a cell-type-specific manner by two independent signal regions. J Virol (1989) 2.43
Monoclonal antibodies to a 28,000 mol. wt protein antigen of Mycobacterium leprae. Clin Exp Immunol (1985) 2.36
Interaction of the lymphocyte-derived Epstein-Barr virus nuclear antigen EBNA-1 with its DNA-binding sites. J Virol (1989) 2.36
Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus DNA. J Virol (1990) 2.35
The 14,000-molecular-weight antigen of Mycobacterium tuberculosis is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. J Bacteriol (1992) 2.33
Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer (1990) 2.28
SKIP, a CBF1-associated protein, interacts with the ankyrin repeat domain of NotchIC To facilitate NotchIC function. Mol Cell Biol (2000) 2.27
Kinesin- and myosin-driven steps of vesicle recruitment for Ca2+-regulated exocytosis. J Cell Biol (1997) 2.23
Stress proteins may provide a link between the immune response to infection and autoimmunity. Int Immunol (1989) 2.21
Generation and characterization of monoclonal antibodies to the phenolic glycolipid of Mycobacterium leprae. Infect Immun (1984) 2.20
A serological test for leprosy with a glycolipid specific for Mycobacterium leprae. Science (1983) 2.18
Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology (1998) 2.17
Organization of repeated regions within the Epstein-Barr virus DNA molecule. J Virol (1980) 2.12
Mapping of T cell epitopes using recombinant antigens and synthetic peptides. EMBO J (1987) 2.09
EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1. J Virol (1994) 2.06
Biological activity of protein antigens isolated from Mycobacterium tuberculosis culture filtrate. Infect Immun (1988) 2.01
Morphological transformation by DNA fragments of human herpesviruses: evidence for two distinct transforming regions in herpes simplex virus types 1 and 2 and lack of correlation with biochemical transfer of the thymidine kinase gene. Cold Spring Harb Symp Quant Biol (1980) 1.99
Comparison of Mycobacterium tuberculosis genomes reveals frequent deletions in a 20 kb variable region in clinical isolates. Yeast (2000) 1.96
Epstein-Barr virus-specific RNA. I. Analysis of viral RNA in cellular extracts and in the polyribosomal fraction of permissive and nonpermissive lymphoblastoid cell lines. J Virol (1976) 1.92
P32/TAP, a cellular protein that interacts with EBNA-1 of Epstein-Barr virus. Virology (1997) 1.87
Biochemical and antigenic characterization of the Mycobacterium tuberculosis 71kD antigen, a member of the 70kD heat-shock protein family. Mol Microbiol (1989) 1.85
Raised serum IgG and IgA antibodies to mycobacterial antigens in rheumatoid arthritis. Ann Rheum Dis (1989) 1.85
Localization of the coding region for an Epstein-Barr virus early antigen and inducible expression of this 60-kilodalton nuclear protein in transfected fibroblast cell lines. J Virol (1985) 1.85
Detyrosination of tubulin regulates the interaction of intermediate filaments with microtubules in vivo via a kinesin-dependent mechanism. Mol Biol Cell (1999) 1.84
A replication function associated with the activation domain of the Epstein-Barr virus Zta transactivator. J Virol (1996) 1.76
Bacterial glycoproteins: a link between glycosylation and proteolytic cleavage of a 19 kDa antigen from Mycobacterium tuberculosis. EMBO J (1996) 1.74
Screening of a recombinant mycobacterial DNA library with polyclonal antiserum and molecular weight analysis of expressed antigens. Infect Immun (1987) 1.74
Identification of a Mycobacterium tuberculosis gene that enhances mycobacterial survival in macrophages. J Bacteriol (2000) 1.73
Three pathways for trehalose biosynthesis in mycobacteria. Microbiology (2000) 1.73
Most Mycobacterium leprae carbohydrate-reactive monoclonal antibodies are directed to lipoarabinomannan. Infect Immun (1987) 1.73
Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol (1998) 1.72
Carboxyl-terminal domain of the Epstein-Barr virus nuclear antigen is highly immunogenic in man. Proc Natl Acad Sci U S A (1985) 1.70
Genetic and immunological analysis of Mycobacterium tuberculosis fibronectin-binding proteins. Infect Immun (1991) 1.69
Cloning and characterization of MEK6, a novel member of the mitogen-activated protein kinase kinase cascade. J Biol Chem (1996) 1.68
Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol (2001) 1.66
A novel approach to the identification of T-cell epitopes in Mycobacterium tuberculosis using human T-lymphocyte clones. Immunology (1987) 1.63
Whistle blowers. BMJ (1992) 1.63
Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection. Nat Med (2001) 1.61
Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J Virol (2000) 1.57
Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol (1991) 1.57
Epstein-Barr virus immortalization: Notch2 interacts with CBF1 and blocks differentiation. J Virol (1997) 1.56
Paleopathological and biomolecular study of tuberculosis in a medieval skeletal collection from England. Am J Phys Anthropol (2001) 1.56
Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure. J Virol (1993) 1.55
Biochemical characterization of extracellular proteases from Vibrio cholerae. Infect Immun (1982) 1.54
Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis (2006) 1.53
A role for SKIP in EBNA2 activation of CBF1-repressed promoters. J Virol (2000) 1.53
Contribution of conserved amino acids in mediating the interaction between EBNA2 and CBF1/RBPJk. J Virol (1995) 1.51
Elevated IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic of patients with rheumatoid arthritis. Scand J Immunol (1989) 1.49
A second Epstein-Barr virus early antigen gene in BamHI fragment M encodes a 48- to 50-kilodalton nuclear protein. J Virol (1985) 1.49
Mta has properties of an RNA export protein and increases cytoplasmic accumulation of Epstein-Barr virus replication gene mRNA. J Virol (1998) 1.46
Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol Cell Biol (1995) 1.45
Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits Mycobacterium smegmatis-induced cytokine production by human macrophages in vitro. Infect Immun (2001) 1.44
Focal therapy in prostate cancer-report from a consensus panel. J Endourol (2010) 1.43
Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect Immun (1997) 1.41
Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol (2001) 1.39
Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria. J Infect Dis (2000) 1.39
The lived experience of women who undergo prenatal diagnostic testing due to elevated maternal serum alpha-fetoprotein screening. MCN Am J Matern Child Nurs (1998) 1.38
Alteration of a single amino acid residue reverses fosfomycin resistance of recombinant MurA from Mycobacterium tuberculosis. Microbiology (1999) 1.33
The identification of T cell epitopes in Mycobacterium tuberculosis using human T lymphocyte clones. Lepr Rev (1986) 1.32
Nuclear localization of CBF1 is regulated by interactions with the SMRT corepressor complex. Mol Cell Biol (2001) 1.31
The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins. J Virol (1998) 1.31
The cost of radiotherapy treatments on a linear accelerator. Br J Radiol (1983) 1.31
A gene from Mycobacterium tuberculosis which is homologous to the DnaJ heat shock protein of E. coli. Nucleic Acids Res (1988) 1.28
Epstein-Barr virus (P3HR-1) defective DNA codes for components of both the early antigen and viral capsid antigen complexes. Virology (1984) 1.27
The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity. Proc Natl Acad Sci U S A (1999) 1.27
Structure of mycobacterial antigens. Br Med Bull (1988) 1.27
A postgenomic approach to identification of Mycobacterium leprae-specific peptides as T-cell reagents. Infect Immun (2000) 1.24